Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹Zr-Labeled Anti-PD-L1 Antibody Formats

Alizée Bouleau; Hervé Nozach; Steven G. DuBois; Dimitri Kereselidze; Céline Chevaleyre; Cheng‐I Wang; Michael J. Evans; Vincent Lebon; Bernard Maillère; Charles Truillet

doi:10.2967/jnumed.121.262967

December 21, 2021Journal of Nuclear MedicineOpen Access

Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹Zr-Labeled Anti-PD-L1 Antibody Formats

View Full Paper

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

This study highlights the potential of designing radioligands with shorter pharmacokinetics for PD-L1 immuno-PET imaging in a preclinical model and encourages further clinical translation of such radioligands.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bouleau et al. (2021) studied this question.

synapsesocial.com/papers/6a033e4a200d7a04bd755d90 https://doi.org/10.2967/jnumed.121.262967

View Full Paper

Ask AI

Bookmark

Share

Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹Zr-Labeled Anti-PD-L1 Antibody Formats

Abstract

Ask about this paper

Discussion

Cite This Study

Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹Zr-Labeled Anti-PD-L1 Antibody Formats

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading